![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2024
Anzahl der Publikationen: 1
2024
Scheubeck, Gabriel 
ORCID: https://orcid.org/0009-0004-2546-6154; Hoffmann, Martin; Jurinovic, Vindi; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Unterhalt, Michael; Schmidt, Christian; Böck, Hans-Peter; Dührsen, Ulrich; Kaesberger, Joachim; Kremers, Stephan; Lindemann, Hans-Walter; Mantovani, Luisa; Hiddemann, Wolfgang; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2024):
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
In: Annals of Hematology, Bd. 103: S. 2373-2380
[PDF, 1MB]
ORCID: https://orcid.org/0009-0004-2546-6154; Hoffmann, Martin; Jurinovic, Vindi; Fischer, Luca ORCID: https://orcid.org/0000-0003-2444-416X; Unterhalt, Michael; Schmidt, Christian; Böck, Hans-Peter; Dührsen, Ulrich; Kaesberger, Joachim; Kremers, Stephan; Lindemann, Hans-Walter; Mantovani, Luisa; Hiddemann, Wolfgang; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2024):
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
In: Annals of Hematology, Bd. 103: S. 2373-2380
[PDF, 1MB]